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Noninvasive Biomarker for Predicting 
Treatment Response to Concurrent 
Chemoradiotherapy in Patients with 
Hepatocellular Carcinoma
INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the 
liver. Although surgical resection and liver transplantation are potentially curative, only 
a small number of patients are candidates for surgery at the time of diagnosis due to 
Received: May 13, 2019
Revised: August 12, 2019
Accepted: August 22, 2019
*Yong Eun Chung and Jun Yong 
Park contributed equally to this 
work.
Correspondence to: 
Mi-suk Park, M.D., Ph.D.
Department of Radiology, Yonsei 
University College of Medicine, 
50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 03722, Korea.
Tel. +82-2-2228-7400 
Fax. +82-2-2227-8337
E-mail: radpms@yuhs.ac
Jinsil Seong, M.D., Ph.D.
Department of Radiation 
Oncology, Yonsei Cancer Center, 
Yonsei University College of 
Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, 
Korea.
Tel. +82-2-2228-8111
Fax. +82-2-2227-7823
E-mail: jsseong@yuhs.ac
iMRI 2019;23:351-360 https://doi.org/10.13104/imri.2019.23.4.351
Original Article 
Purpose: To investigate noninvasive biomarkers for predicting treatment response in 
patients with locally advanced HCC who underwent concurrent chemoradiotherapy 
(CCRTx). 
Materials and Methods: Thirty patients (55.5 ± 10.2 years old, M:F = 24:6) who 
underwent CCRTx due to advanced HCC were enrolled. Contrast-enhanced US (CEUS) 
and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) were 
obtained before and immediately after CCRTx. The third CEUS was obtained at one 
month after CCRTx was completed. Response was assessed at three months after 
CCRTx based on RECIST 1.1. Quantitative imaging biomarkers measured with CEUS 
and MRI were compared between groups. A cutoff value was calculated with ROC 
analysis. Overall survival (OS) was compared by the Breslow method. 
Results: Twenty-five patients were categorized into the non-progression group and 
five patients were categorized into the progression group. Peak enhancement of the 
first CEUS before CCRTx (PE1) was significantly lower in the non-progression group 
(median, 18.6%; IQR, 20.9%) than that in the progression group (median, 59.1%; 
IQR, 13.5%; P = 0.002). There was no significant difference in other quantitative 
biomarkers between the two groups. On ROC analysis, with a cutoff value of 42.6% 
in PE1, the non-progression group was diagnosed with a sensitivity of 90.9% and a 
specificity of 100%. OS was also significantly longer in patients with PE1 < 42.6% (P 
= 0.014). 
Conclusion: Early treatment response and OS could be predicted by PE on CEUS 
before CCRTx in patients with HCC.
Keywords: Hepatocellular carcinoma; Ultrasonography; Perfusion imaging; 
Magnetic resonance imaging, Chemoradiotherapy, Biomarkers
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advanced stage of HCC, poor liver function, or organ donor 
shortage (1, 2). In non-operable HCC cases, several non-
surgical treatment methods exist for HCC, including local 
ablation, transarterial chemoembolization or chemoinfusion, 
antiangiogenic drugs, and intra-arterial radiotherapy 
(1). Concurrent chemoradiotherapy (CCRTx) has recently 
been reported as an alternative option for treating locally 
advanced HCC that can increase patient survival (3-5). 
CCRTx can also be used to downstage HCC or to bridge 
therapy until liver transplantation (6, 7).
In an era in which various treatment options are available 
for HCC, early prediction of treatment response can allow 
treatment options to be chosen or changed to fit each 
individual patient. Tumor microenvironments might change 
in response to treatment. Dynamic contrast-enhanced 
(DCE) imaging studies can detect these microenvironmental 
changes by quantitative measurement of tissue perfusion 
(8). According to previous studies, tumor response and 
survival of HCC patients treated with sorafenib and 
metronomic tegafur/uracil (9), sunitinib (10), transarterial 
chemoembolization (11), and conventional radiotherapy 
(12) can be predicted with DCE MRI. In CCRTx, treatment 
outcome depends on oxygen status of the tumor tissue 
and intra-tumoral vascular status including blood supply 
and vessel leakage that are closely related to perfusion 
parameters. Hence, DCE imaging studies can potentially 
predict treatment response in patients who undergo CCRTx.
Recently, attempts have been made to use contrast-
enhanced US (CEUS) to evaluate treatment response instead 
of DCE MRI which is less accessible to patients due to high 
cost, longer scanning time, and the necessity of gadolinium 
contrast media administration. CEUS is more accessible 
with less effect on renal function than DCE MRI. Several 
experimental and clinical studies have evaluated the 
feasibility of ultrasound contrast media to predict treatment 
response (13-15). However, most of these past studies were 
focused on the treatment effect of antiangiogenic drugs 
using qualitative or semiquantitative methods to evaluate 
disappearance of arterial enhancing portion or proportion 
changes of non-enhancing area to total cross-sectional area 
after treatment (14, 16, 17). To the best of our knowledge, 
the use of quantitative methods to evaluate the feasibility 
of CEUS and DCE MRI in patients who undergo CCRTx has 
not been reported yet. Therefore, the purpose of this study 
was to investigate the feasibility of DCE MRI and CEUS 
as noninvasive biomarkers for the prediction of treatment 
response in patients with locally advanced HCC.
MATERIALS AND METHODS
Patients
This prospective study was approved by the institutional 
review board of Yonsei University College of Medicine. 
Informed consent was acquired from all patients. All data 
were handled in accordance with HIPAA compliance. 
Between June 2011 and March 2013, 34 patients who were 
first diagnosed with locally advanced HCC and for whom 
CCRTx was planned were consecutively enrolled in this 
study. Exclusion criteria were: 1) patients who had received 
any other prior treatment including surgery, transarterial 
chemoembolization, transarterial chemoinfusion, systemic 
chemotherapy, intra-arterial chemotherapy, antiangiogenic 
therapy, and local ablation such as radiofrequency ablation 
and cryotherapy, 2) patients with evidence of distant 
metastasis, 3) patients under 20 years of age, 4) patients 
with hypersensitivity to MRI or US contrast agents, 4) 
patients who were pregnant, lactating or of childbearing 
potential, and 5) patients with impaired renal function (eGFR 
< 30) or on dialysis. 
Study Protocol
The study protocol is summarized in Figure 1. After 
initial screening, a chemoport was inserted via the femoral 
artery and an infusion catheter was placed in the common 
hepatic artery. CCRTx was administered for five weeks (Fig. 
1). Radiotherapy with a total dose of 45 Gy was done with 
25 fractions of 1.8 Gy. During radiotherapy, a concurrent 
continuous infusion of 5-flurouracil (5-FU) at a dose of 
500 mg/m2/day was administered through the chemoport. 
After CCRTx, patients received hepatic arterial infusion 
chemotherapy with 5-FU (500 mg/m2/day for 5 hours) for 
Fig. 1. Study protocol. DEC MRI and CEUS were performed 
before (MRI1 and CEUS1) and immediately after CCRTx (MRI2 
and CEUS2). CEUS was also performed one month after 
CCRTx (CEUS3).
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three consecutive days and cisplatin (60 mg/m2/day) on 
day 2 of their monthly cycles for 3-12 cycles depending 
on tumor response (18, 19). DCE MRI and CEUS were 
performed before CCRTx was initiated (MRI1 and CEUS1) and 
immediately after CCRTx was completed (MRI2 and CEUS2). 
DCE MRI and CEUS were performed on the same day. In 
addition, CEUS was performed one month after CCRTx was 
completed (CEUS3). Afterwards, CT was usually performed 
every 2-3 months to evaluate tumor response. Additional 
imaging examinations including CT, MRI, US, and PET were 
performed depending on patient status. Time intervals 
between MRI1/CEUS1 and MRI2/CEUS2 and between MRI2/
CEUS2 and CEUS3 were 32.6 ± 5.1 days and 31.8 ± 4.6 days, 
respectively.
MRI and CEUS Protocol 
All MRI examinations were performed in a 3T system 
(Magnetom Trio, Siemens, Erlangen, Germany) with 
6-channel body coils. First, a survey scan (HASTE; repetition 
time [TR]/echo time [TE], 500/95 msec; matrix, 256 × 205; 
slice thickness, 8 mm; slice spacing, 9.6 mm; flip angle, 
2°; scanning time, 19 sec) and fat-saturated axial T2WI 
(turbo spon echo [TSE]; TR/TE, 2000/81 msec; matrix, 320 × 
205; slice thickness, 4 mm; slice spacing, 5 mm, flip angle, 
140°; scanning time; with navigation) were acquired for 
localization. In addition to DCE MRI, diffusion-weighted 
imaging (DWI) was acquired. DWI (echo planar imaging with 
spectral presaturation attenuated by inversion recovery; TR/
TE, 6100/69 msec; matrix, 192 × 108; slice thickness, 5 mm; 
slice spacing, 6 mm, flip angle, 90°; with free breathing) 
was acquired with three b values (50, 400, 800 s/mm2). 
Apparent diffusion coefficient (ADC) map was automatically 
generated on the console using mono-exponential model. 
In terms of DCE MRI, dual flip angle T1WI (3D VIBE; TR/TE, 
4.91/1.71 msec; matrix, 192 × 138; slice thickness, 3.6 mm; 
flip angle, 2° and 14.6°) was first acquired to estimate T1 
map. DCE MRI (TWIST; TR/TE, 4.51/1.76 msec; matrix, 192 × 
138; slice thickness, 3.6 mm; flip angle, 12°) was acquired 
after a bolus injection of gadodiamide (Omniscan; GE 
Healthcare, Oslo, Norway) at a dose of 0.1 mmol/kg (0.2 mL/
kg) with an injection rate of 5 mL/sec followed by a 30 mL 
saline flush. Twenty slices (range, 10 cm) with an acquisition 
time of 0.295 sec/slice were acquired while centered on 
the center of the tumor in one cycle (total scanning time of 
one cycle, 5.9 sec). A total of 75 image sets were acquired 
during approximately 7-8 min.
CEUS was performed by one experienced radiologist using 
an ACUSON S2000 (Siemens AG, Erlangen, Germany) with a 
4C1 curved transducer at contrast-specific mode (Cadence 
Contrast Pulse Sequence, CPS technology). Before CEUS, 
conventional US was performed to locate the tumor. The 
location of the transducer was fixed to visualize the tumor 
as large as possible. Contrast media (Sonovue, Bracco, 
Milan, Italy) was administered via the arm vein at a dose 
of 2.4 mL. During CEUS, patients were instructed to take 
shallow breaths. The mechanical index was set to 0.07. 
Real-time CEUS was stored as a 90-sec video clip taken 
after the contrast medium was injected for quantitative 
analysis.
Image Analysis
MR images were sent to a picture achieving and 
communication system (PACS, Centricity RA1000, GE 
Healthcare, Milwaukee, WI, USA). ADC values were 
measured on PACS. Three circular regions of interest 
(ROIs) were drawn within the tumor as large as possible 
on the ADC map and average ADC values were calculated. 
Quantitative DCE parameters were calculated and measured 
with dedicated software (Tissue 4D, Siemens, Erlangen, 
Germany) based on the modified Tofts model in a post-
processing workstation (Leonardo, Siemens, Erlangen, 
Germany). At first, motion correction was performed by 
a non-rigid body algorithm followed by registration of 
the T1 map to the dynamic images. A DCE map was then 
generated (19). At least three ROIs were drawn around the 
tumor margin at different slices of the DCE map. Mean 
values of volume transfer constant from blood plasma to 
extracellular extravascular space (Ktrans, min-1), rate constant 
from blood plasma to extracellular extravascular space (Kep,, 
min-1), and extravascular extracellular volume fraction (Ve 
= Ktrans/Kep, %) were measured (Fig. 2a). CEUS was analyzed 
using dedicated software (contrast dynamics software, 
Siemens) installed on an ACUSON S2000. Quantitative 
CEUS parameters including peak enhancement (PE, %), 
time to peak enhancement (TTP, seconds), and mean transit 
time (MTT, seconds) were calculated by gamma variate 
processing (Fig. 2b). PE was defined as the maximum 
amplitude of the curve. It was calculated as the percentage 
of peak enhancement contrast signal to full-scale contrast 
signal. If the contrast image within the ROI was full white, 
PE was 100%. TTP was defined as the time interval between 
contrast media administration and peak enhancement in 
the ROI. MTT was defined as the average time required 
to reach half of the gamma-variate curve area (20). After 
loading and reviewing CEUS clips, circular ROIs were drawn 
within the tumor as large as possible. Measurements were 
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taken at least three times. Average values of quantitative 
parameters were calculated. 
Clinical Data Acquisition and Tumor Assessment
Clinical data including age, sex, Eastern Cooperative 
Oncology Group (ECOG) performance status score, etiology 
of chronic liver disease, tumor size, presence or absence 
of vessel invasion, TNM stage, Child-Pugh class, alpha- 
fetoprotein (AFP) level, level of protein induced by vitamin 
K absence/antagonist-II (PIVKA II), and retention rate of 
indocyanine green 15 min after administration (ICG R15) 
were collected from medical records. Tumors were assessed 
with a 3-month follow-up CT after CCRTx was completed 
based on Response Evaluation Criteria in Solid Tumors 
1.1 (RECIST 1.1). Based on follow-up imaging taken three 
months after CCRTx, patients who showed partial response 
or stable disease were categorized into a non-progression 
group while patients who showed disease progression 
were categorized into a progression group. Progression-
free survival (PFS) was defined as the interval between the 
date of patient enrollment and that of tumor progression. 
Overall survival (OS) was defined as the interval from the 
date of patient enrollment to death. PFS and OS were both 
calculated from the date of enrollment to December 31, 
2016.
Statistical Analysis
Mann-Whitney U test was used for continuous variables 
whereas Chi-square test or Fisher’s exact test was used 
for categorical variables to compare non-progression 
and progression groups. Repeated measures ANOVA or 
Mann-Whitney U test was used to compare differences 
in parameters according to acquired time. Youden index 
(sensitivity + specificity -1) was calculated and optimal 
cutoff points of variables were determined to maximize 
the Youden index. Sensitivity and specificity for differential 
diagnosis were calculated using optimal cutoff values for 
non-progression and progression groups. Patients were 
divided into the two groups using these cutoff values. PFS 
and OS were compared for each group using the Kaplan-
Meier method with the Breslow technique. A P value of less 
than 0.05 was considered statistically significant.
RESULTS
Among 34 patients, four patients were excluded (death 
before CCRTx completion [n = 1], administration of only 
palliative RTx [n = 2], and administration of transarterial 
chemoembolization during chemoport insertion [n = 1]). 
Finally, 30 patients were enrolled in this study. The mean 
age of these enrolled 30 patients was 55 years old (range, 
28-71 years) and the sex ratio was 24:6 (M:F) (Table 1). 
Among these 30 patients, 25 patients were categorized 
into the non-progression group (partial response, n = 17; 
stable disease, n = 8) and the remaining five patients were 
Fig. 2. Quantitative analysis of DCE MRI (a) and CEUS (b). (a) ROI was drawn with a dedicated program (Tissue 4D) as large 
as possible on the axial MR image to include the largest proportion of the tumor in DCE MRI. Ktrans, Kep and Ve values were 
calculated within the ROI. (b) In CEUS, the ROI was drawn as large as possible on the slice most similar to the MR image 
using dedicated software and PE, TTP and MTT were calculated. 
a b
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categorized into the progression group. Demographics of all 
patients and those of the non-progression and progression 
groups are summarized in Table 1. There were no significant 
differences in age, sex, ECOG performance score, etiology of 
chronic liver disease, tumor size, presence of vessel invasion, 
TNM stage, Child-Pugh class, AFP level, or PIVKA II level 
between non-progression and non-progression groups (Table 
1). PFS was longer in the non-progression group (mean, 
716.2 days; standard error [SE], 134.6 days) than that in 
the progression group (mean, 84.8 days; SE, 17.2 days) 
(P < 0.001). OS was also significantly longer in the non-
progression group (mean, 987.9 days; SE, 147.2 days) than 
that in the progression group (mean, 181.4 day; SE, 27.2 
days, P < 0.001). 
Quantitative parameters measured by MRI and CEUS 
are summarized in Table 2. PE1 was significantly (P = 
Table 1. Patient Demographics
All patients Non-progression group (n = 25) Progression group (n = 5) P value
Age, median years (range) 55 (28-71) 57 (28-71) 49 (45-57) 0.122
Gender (%)
     Male 24 (80) 20 (80) 4 (80) > 0.999
     Female 6 (20) 5 (20) 1 (20)
ECOG PS (%)
     0 15 (50) 14 (56) 1 (20) 0.33
     1-2 15 (50) 11 (44) 4 (80)
Etiology
     HBC 25 (83.3) 21 (84) 4 (80) 0.604
     HCV 3 (10) 2 (8) 1 (20)
     NBNC 2 (6.7) 2 (8) 0 (0)
Size (cm), median (range) 93.6 (38.3-148.4) 57.8 (38.3-148.4) 105.1 (83.4-119.3) 0.784
Vessel invasion (%)
     No 12 (40) 10 (40) 2 (40) > 0.999
     Yes 18 (60) 15 (60) 3 (60)
TNM stage (%)
     1 1 (3.3) 1 (4) 0 0.966
     2 11 (36.7) 9 (36) 2 (40)
     3 7 (23.3) 6 (24) 1 (20)
     4 11 (36.7) 9 (36) 2 (40)
Child-Pugh class (%)
     A 27 (90) 22 (88) 5 (100) > 0.999
     B 3 (10) 3 (12) 0
AFP (%)
     < 200 ng/ml 14 (46.7) 13 (52) 1 (20) 0.336
     ≥ 200 ng/ml 16 (53.3) 12 (48) 4 (80)
PIVKA-II (%)
     < 2000 mAU/ml 17 (56.7) 15 (60) 2 (40) 0.41
     ≥ 2000 mAU/ml 13 (43.3) 10 (40) 3 (60)
ICG R15 10.1 (1.8-39.1) 12.2 (1.8-32.2) 10.1 (2.6-39.1) 0.418
AFP = alpha-fetoprotein; ECOG PS = Eastern Cooperative Oncology Group Performance Status; HBC = hepatitis B carrier; HCV = hepatitis C carrier; ICG R15 = indocyanine 
green retention test; NBNC = non-B, non-C; PIVKA-II = protein induced by vitamin K absence/antagonist-II
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0.002) lower in the non-progression group than that in 
the progression group (Fig. 3). There were no significant 
differences in other quantitative parameters between the 
two groups. On ROC analysis, with a cutoff value of 42.6%, 
the sensitivity and specificity for discriminating the non-
progression group from the progression group was 90.9% 
and 100%, respectively. When patients were divided into 
two subgroups based on the cutoff value, patients with PE 
≤ 42.6% showed better PFS (P = 0.020) and OS (P = 0.032) 
than patients with PE > 42.6% (Fig. 4).
In a subgroup analysis of the non-progression group, ADC 
values (P < 0.001) and Ve (P = 0.025) were significantly 
increased in MRI2 compared to those in MRI1 (Fig. 5). For 
CEUS parameters, there were no significant differences in 
PE (P = 0.055), TTP (P = 0.460), or MTT (P = 0.809) among 
the three CEUS examinations, although all three values 
continuously decreased in follow-up CEUS examinations. 
A subgroup analysis was not performed for the progression 
group because of its small number of patients. 
DISCUSSION
Our results showed that treatment response could be 
predicted by PE on CEUS before CCRTx in patients who 
underwent CCRTx due to locally advanced HCC. Patients 
with lower PE before treatment showed better response to 
CCRTx compared to patients with higher PE. All DCE MRI 
parameters could not predict treatment response before 
CCRTx. On serial follow-up in the non-progression group, 
a b c
d e f
Fig. 3. A 48-year-old male with locally advanced HCC. Huge hypervascular HCC with central necrosis was noted mainly in 
the left hepatic lobe in pretreatment (a-c), immediate (d-f) and 3 months after the end of CCRTx (g, h). PE was 40.8% in 
pretreatment CEUS, 47.8% immediately after CCRTx, and 10.2% at one month after CCRTx. (i) Three months after CCRTx 
was completed, both size and vascularity of the tumor decreased. The patient underwent left extended hemihepatectomy. 
On pathologic examination, there was 95% tumor necrosis. The patient was followed until the end of this study (December 
31, 2016) without tumor recurrence (OS = 1943 days).
g h i
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a b
Fig. 4. Progression-free survival (a) and 
overall survival (b). Patients with PE < 
42.6% showed better progression-free 
survival (P = 0.020) and overall survival 
(P = 0.032) than patients with PE ≥ 
42.6%. 
a b c
d e f
g
Fig. 5. DWI (a) DCE MRI (b-d) and CEUS (e-g) parameter changes. (a) ADC values 
(P < 0.001) and (d) Ve (P = 0.025) in DCE MRI significantly increased immediately 
after CCRTx, whereas the CEUS parameters showed no significant changes (P > 
0.05). 
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ADC values and Ve significantly increased after CCRTx 
compared to pretreatment values, whereas there were no 
significant changes in CEUS parameters among the three 
consecutive CEUS examinations.
Radiation therapy can induce cell death either by direct 
or indirect DNA damage or by vascular damage, resulting in 
changes in intratumoral microenviroment (21). A lower PE 
might indicate that a lower number of blood vessels within 
the HCC will be effectively damaged by the same radiation 
dose compared to HCC with high PE, resulting in worse 
clinical outcomes for HCC with low PE. We might also 
assume that hypoxia can decrease response to radiation 
therapy as anoxic cells are more resistant to radiation than 
others during radiation therapy (22, 23). However, very 
low oxygen concentrations (about 10 Torr) are enough for 
oxygen to act as an adequate radiation sensitizer during 
RTx (22). Blood flow was maintained during CCRTx and 
one month after CCRTx in this study, although it did show 
continuous decrease. Hence, tumor oxygen levels might 
have been maintained above 10 Torr, the minimum required 
for oxygen to work as a radiation sensitizer even in HCC 
with lower PE. 
According to a previous study, blood flow to tumors is 
increased immediately after radiation therapy on contrast-
enhanced Doppler US (24). In our study, all CEUS parameters 
decreased immediately after treatment and at one month 
after treatment with or without statistical significance. This 
discrepancy might be because of differences in radiotherapy 
methods and CEUS techniques. The previous study 
performed proton radiotherapy with semi-quantitative CEUS 
analysis using a 1st generation US contrast agent whereas 
our study performed CCRTx with quantitative analysis using 
a 2nd generation US contrast agent and contrast-specific 
mode.
Previous studies have determined whether DCE MRI can 
be used to evaluate treatment response in various tumors 
including HCC and reported contradictory results depending 
on the treatment method chosen and DEC MRI parameters 
evaluated (25-27). Some studies reported that pretreatment 
DCE parameters in HCC patients who underwent radiation 
therapy did not significantly differ between non-progression 
and progression groups (19, 28) whereas an increased slope 
and peak observed within two weeks after radiotherapy was 
associated with better local response. These results were 
comparable with our study results in that initial DCE MRI 
parameters were not significantly different between non-
progression and progression groups while Ve significantly 
increased after CCRTx compared to pretreatment DCE Ta
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MRI. Ve is defined as the extracellular extravascular space 
fraction (= Ktrans/Kep) (23). After radiotherapy, K
trans (the 
volume transfer constant from blood plasma to extracellular 
extravascular space) might increase due to loss of vessel 
integrity and Kep (the rate constant from extravascular 
extracellular space to blood plasma) might decrease due to 
increased extravascular extracellular space by cell death, 
which might result in an increase in Ve after treatment.
A higher ADC suggests lower cellularity or the presence 
of necrosis (19). In a study by Kim et al. (19), higher 
pretreatment ADC values were associated with better PFS 
in patients with CCRTx. These results were comparable 
with our study results as we found that ADC values were 
higher in the non-progression group than those in the 
progression group, although the difference between the two 
was not statistically significant. Furthermore, ADC values 
significantly increased immediately after CCRTx in the non-
progression group possibly due to decreased cellularity 
within the HCC after treatment.
This study has several limitations. First, the number 
of total patients and the proportion of patients in the 
progression group were relatively small. Second, only a 
2-dimensional evaluation of tumors was done, although 
three consecutive slides of MRI which included the largest 
tumor size were evaluated in efforts to overcome this 
limitation. Third, the relationship between pathology change 
and DCE MRI/CEUS parameters could not be determined 
because most patients had locally advanced HCC. They did 
not undergo surgery after treatment. Fourth, the number 
of enrolled patients was relatively small. Further studies 
with larger study populations are warranted in the future to 
investigate biomarkers that can monitor treatment response 
during CCRTx.
In conclusion, early treatment response and OS could 
be predicted by PE on CEUS before CCRTx in patients 
with locally advanced HCC. In addition, ADC values 
and Ve significantly increased after CCRTx compared to 
pretreatment values in the non-progression group.
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